The treatment of advanced renal cell cancer with interleukin-2. Based immunotherapy

The target is hit only in part

M. Maffezzini

Research output: Contribution to journalArticle

Abstract

A rather wide clinical experience in the treatment of metastatic renal cell cancer with rIL-2 based regimens has been accumulated over the last ten years. It appears that overall clinical responses are observed in 25% of the patients but less than 30% of the responses reach one year in duration. The target is only partially hit. To achieve more tangible clinical results we should concentrate on several aspects. First, a more accurate selection of patients that could be based on the assessment of biological parameters associated with positive clinical outcome (i.e. total lymphocyte counts, NK/LAK activity, eosinophil levels), and on the detection of substances known to exert a depressive effect on rIL-2 activity (i.e. TGF-B, PGE-2, neopterin, IL-10) at baseline and their evolution during treatment. Second, it is apparent that the standard schedules of administration of immunotherapy are suboptimal to trigger the threshold of the immune response in the averge cancer patient. Our background experiences now are sufficient to justify the exploration of different schedules and dosages. Third, the association of immunotherapy with cytotoxic drugs is worth studying although the ideal compound, dosage and schedule are still to be defined. Finally, it is crucial to investigate supplementary forms of treatment like, for example, the transduction of tumor cells with genes to obtain an elevated production of cytokines at tumor sites.

Original languageEnglish
Pages (from-to)301-304
Number of pages4
JournalActa Urologica Italica
Volume10
Issue number4
Publication statusPublished - 1996

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Appointments and Schedules
Neopterin
Neoplasms
Lymphocyte Count
Prostaglandins E
Eosinophils
Interleukin-10
Patient Selection
Therapeutics
Cytokines
Pharmaceutical Preparations
Genes

Keywords

  • interleukin-2
  • renal cell cancer

ASJC Scopus subject areas

  • Urology

Cite this

The treatment of advanced renal cell cancer with interleukin-2. Based immunotherapy : The target is hit only in part. / Maffezzini, M.

In: Acta Urologica Italica, Vol. 10, No. 4, 1996, p. 301-304.

Research output: Contribution to journalArticle

@article{13c420a811ce40b5adc6ab54d4475d65,
title = "The treatment of advanced renal cell cancer with interleukin-2. Based immunotherapy: The target is hit only in part",
abstract = "A rather wide clinical experience in the treatment of metastatic renal cell cancer with rIL-2 based regimens has been accumulated over the last ten years. It appears that overall clinical responses are observed in 25{\%} of the patients but less than 30{\%} of the responses reach one year in duration. The target is only partially hit. To achieve more tangible clinical results we should concentrate on several aspects. First, a more accurate selection of patients that could be based on the assessment of biological parameters associated with positive clinical outcome (i.e. total lymphocyte counts, NK/LAK activity, eosinophil levels), and on the detection of substances known to exert a depressive effect on rIL-2 activity (i.e. TGF-B, PGE-2, neopterin, IL-10) at baseline and their evolution during treatment. Second, it is apparent that the standard schedules of administration of immunotherapy are suboptimal to trigger the threshold of the immune response in the averge cancer patient. Our background experiences now are sufficient to justify the exploration of different schedules and dosages. Third, the association of immunotherapy with cytotoxic drugs is worth studying although the ideal compound, dosage and schedule are still to be defined. Finally, it is crucial to investigate supplementary forms of treatment like, for example, the transduction of tumor cells with genes to obtain an elevated production of cytokines at tumor sites.",
keywords = "interleukin-2, renal cell cancer",
author = "M. Maffezzini",
year = "1996",
language = "English",
volume = "10",
pages = "301--304",
journal = "Acta Urologica Italica",
issn = "0394-2511",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - The treatment of advanced renal cell cancer with interleukin-2. Based immunotherapy

T2 - The target is hit only in part

AU - Maffezzini, M.

PY - 1996

Y1 - 1996

N2 - A rather wide clinical experience in the treatment of metastatic renal cell cancer with rIL-2 based regimens has been accumulated over the last ten years. It appears that overall clinical responses are observed in 25% of the patients but less than 30% of the responses reach one year in duration. The target is only partially hit. To achieve more tangible clinical results we should concentrate on several aspects. First, a more accurate selection of patients that could be based on the assessment of biological parameters associated with positive clinical outcome (i.e. total lymphocyte counts, NK/LAK activity, eosinophil levels), and on the detection of substances known to exert a depressive effect on rIL-2 activity (i.e. TGF-B, PGE-2, neopterin, IL-10) at baseline and their evolution during treatment. Second, it is apparent that the standard schedules of administration of immunotherapy are suboptimal to trigger the threshold of the immune response in the averge cancer patient. Our background experiences now are sufficient to justify the exploration of different schedules and dosages. Third, the association of immunotherapy with cytotoxic drugs is worth studying although the ideal compound, dosage and schedule are still to be defined. Finally, it is crucial to investigate supplementary forms of treatment like, for example, the transduction of tumor cells with genes to obtain an elevated production of cytokines at tumor sites.

AB - A rather wide clinical experience in the treatment of metastatic renal cell cancer with rIL-2 based regimens has been accumulated over the last ten years. It appears that overall clinical responses are observed in 25% of the patients but less than 30% of the responses reach one year in duration. The target is only partially hit. To achieve more tangible clinical results we should concentrate on several aspects. First, a more accurate selection of patients that could be based on the assessment of biological parameters associated with positive clinical outcome (i.e. total lymphocyte counts, NK/LAK activity, eosinophil levels), and on the detection of substances known to exert a depressive effect on rIL-2 activity (i.e. TGF-B, PGE-2, neopterin, IL-10) at baseline and their evolution during treatment. Second, it is apparent that the standard schedules of administration of immunotherapy are suboptimal to trigger the threshold of the immune response in the averge cancer patient. Our background experiences now are sufficient to justify the exploration of different schedules and dosages. Third, the association of immunotherapy with cytotoxic drugs is worth studying although the ideal compound, dosage and schedule are still to be defined. Finally, it is crucial to investigate supplementary forms of treatment like, for example, the transduction of tumor cells with genes to obtain an elevated production of cytokines at tumor sites.

KW - interleukin-2

KW - renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0029826563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029826563&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 301

EP - 304

JO - Acta Urologica Italica

JF - Acta Urologica Italica

SN - 0394-2511

IS - 4

ER -